Sign up to view the webinar
Abstract
This webinar will discuss how immunophenotyping gene expression of the DeltEx DRI product (γδ T cells engineered to resist chemotherapy) elucidated additional attributes such as cytotoxic and/or trafficking potential and the ability to stimulate immune cell recruitment.
Highlights Include:
• RepSeq+ TCR 4-chain RNA analysis can track shifts in relative amounts of mapped uCDR3 before, during, and after the manufacturing process
• Combined immune repertoire and ImmunoSight immunophentyping analysis indicates that the expanded and activated γδ T cells significantly shifted to an increase of γV9 and δV2 clones and expressed activation, cytotoxicity, and cell migration genes
Visit iRepertoire: https://irepertoire.com/
Mariska ter Haak
Senior Director Analytical Development at IN8bio
Mariska ter Haak is a seasoned immunology and assay development expert with a strong focus on cell and gene therapies. With over 20 years of experience, she has played a key role in advancing cutting-edge therapies at leading biotech and pharma organizations such as IN8Bio and Janssen. Notably, IN8Bio is the first company to clinically administer a genetically modified γδ-T cell therapy to patients.
Mariska’s expertise lies in developing and validating complex assays to support clinical trials, including those for γδ-T cell and influenza vaccine therapies. She is passionate about utilizing her scientific knowledge to drive innovation in the field of immunology and Immuno-oncology and accelerate the development of potential life-saving treatments for patients.
